In HCC, the first evidence of efficacy emerged from a phase Ib trial of combined atezolizumab (IgG1 anti PD-L1) and bevacizumab (anti-VEGF-A) in previously untreated advanced HCC [35]. The gene discussed is CD274; the disease is hepatocellular carcinoma.